BRAIN Biotech has received an €11.51 million milestone payment from Royalty Pharma linked to development progress for deucrictibant. The payment was triggered under BRAIN Biotech's existing royalty monetisation arrangement as development of the investigational therapy reached a contractual milestone. The receipt strengthens BRAIN Biotech's near-term financial position while demonstrating continued value generation from its legacy participation in deucrictibant. Field Content Alert Type Milestone payment Company BRAIN Biotech Counterparty Royalty Pharma Drug / Asset Deucrictibant Payment €11.51 million Transaction Context Existing royalty monetisation agreement What Happened BRAIN Biotech received an €11.51 million development milestone payment from Royalty Pharma. Why It Matters The payment provides a material cash inflow and demonstrates continued economic value from BRAIN Biotech's interest in deucrictibant. Supporting Context The payment arises from an existing Royalty Pharma arrangement rather than a newly signed licensing transaction. Key Takeaway Progress in deucrictibant development has triggered a significant milestone payment to BRAIN Biotech. What to Watch Further clinical and regulatory milestones for deucrictibant and any additional payments arising under the royalty arrangement. Primary Source BRAIN Biotech Relevant Date September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

GENFIT says its MASH diagnostics technology could support more than $1.5 billion in peak US sales by 2033 as the market for non-invasive patient identification expands. The company cited an IQVIA assessment of the commercial opportunity for products based on its NIS diagnostic technology as new MASH treatments increase demand for scalable non-invasive testing. The forecast highlights the growing strategic value of diagnostics capable of identifying, stratifying and monitoring patients as the therapeutic MASH market develops. Field Content Alert Type Diagnostics commercialisation update Company GENFIT Technology NIS diagnostics technology Therapy Area(s) Metabolic dysfunction-associated steatohepatitis (MASH) Geography United States Commercial Estimate More than $1.5 billion in potential peak sales Target Year 2033 Assessment Source IQVIA What Happened GENFIT highlighted an IQVIA estimate indicating that products based on its NIS technology could generate more than $1.5 billion in peak US sales by 2033. Why It Matters The estimate underlines the expanding role of non-invasive diagnostics as pharmaceutical treatment options for MASH increase. Supporting Context MASH patient identification and monitoring remain important commercial and clinical challenges as new therapies enter the market. Key Takeaway GENFIT sees a substantial long-term commercial opportunity for its diagnostics platform alongside growth in the MASH therapeutics market. What to Watch Commercial partnerships, regulatory progress and adoption of NIS-based diagnostics alongside new MASH therapies. Primary Source GENFIT Relevant Date 9 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Transcenta Therapeutics and WuXi Biologics have entered a strategic licensing collaboration covering Transcenta's HiCB continuous bioprocessing technologies and ExcelPro media platform. Under the agreement, WuXi Biologics receives a non-exclusive licence to use Transcenta's HiCB technologies, with Transcenta receiving RMB10 million upfront and potential additional milestone payments. The collaboration broadens commercial access to continuous bioprocessing technology and highlights growing investment in manufacturing productivity across biologics development. Field Content Alert Type Technology licensing agreement Companies Transcenta Therapeutics and WuXi Biologics Technology HiCB continuous bioprocessing technologies Additional Platform ExcelPro media Licence Type Non-exclusive Upfront Payment RMB10 million Additional Economics Potential milestone payments Industry Area Biologics manufacturing What Happened Transcenta granted WuXi Biologics a non-exclusive licence to its HiCB technologies and ExcelPro media platform as part of a strategic collaboration. Why It Matters The agreement supports wider adoption of continuous bioprocessing approaches designed to improve biologics manufacturing efficiency and productivity. Supporting Context Transcenta receives RMB10 million upfront and may receive additional milestone payments. Key Takeaway The collaboration commercialises Transcenta's manufacturing technology through one of the world's largest biologics development and manufacturing providers. What to Watch Deployment of HiCB across WuXi Biologics programmes and achievement of future milestones. Primary Source Transcenta Therapeutics / WuXi Biologics Relevant Date September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Biocon has secured a 10-year pertuzumab supply partnership in Brazil under the country's Productive Development Partnership programme. Biocon, Bahiafarma and Bionovis received full allocation for pertuzumab supply, supporting long-term access to the HER2-targeted breast cancer therapy in the Brazilian market. Biocon is eligible for milestone payments and a share of programme revenues, making the agreement a significant long-term commercial partnership for its oncology biosimilars business. Field Content Alert Type Long-term supply partnership Company Biocon Partners Bahiafarma and Bionovis Product Pertuzumab Therapy Area(s) Oncology Indication HER2-positive breast cancer Geography Brazil Agreement Duration 10 years Programme Productive Development Partnership What Happened Biocon and its Brazilian partners received full allocation under a 10-year programme for the supply of pertuzumab. Why It Matters The agreement provides Biocon with a long-term commercial position in Brazil's oncology market and supports access to a major HER2-targeted therapy. Supporting Context Biocon is eligible for milestone payments and a share of programme revenues under the arrangement. Key Takeaway The 10-year pertuzumab partnership strengthens Biocon's oncology biosimilars footprint in Brazil. What to Watch Technology transfer, supply execution and milestone payments under the programme. Primary Source Biocon Relevant Date September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

General and family physicians in Mexico earned an average salary of MX$10,800 per month in the first quarter of 2026, according to the latest occupational data published by Data México. That represents a 17.3% increase from the previous quarter, when the average salary was approximately MX$9,200 per month. For general practitioners and family physicians working in Mexico, however, the national average tells only part of the story. Pay varies considerably depending on location, and the latest data show a substantial difference between the highest-paying states and the national benchmark. Average salary for general and family physicians in Mexico Data México reports approximately 238,000 people working as general and family physicians in Q1 2026. Their average monthly salary was: MX$10,800 per month Based on 12 months at the reported monthly average, that is equivalent to approximately: MX$129,600 per year The annual figure is a simple annualisation of the monthly Data México figure rather than a separately reported annual salary. The average working week for this occupational group was approximately 39.7 hours. Data México is operated by Mexico's Ministry of Economy and brings together labour-market information from official Mexican statistical sources. GP salaries increased in early 2026 The latest figures suggest a noticeable change in earnings from the end of 2025. In Q4 2025, the reported average salary for general and family physicians was around MX$9,200 per month. By Q1 2026, this had risen to MX$10,800. That amounts to a quarterly increase of approximately 17.3%. A one-quarter increase should not necessarily be interpreted as a permanent rise in GP salaries. Changes in the composition of the workforce, geography, hours worked and the statistical sample can all affect occupational salary estimates. Nevertheless, the latest data provide a useful indication of current earnings within Mexico's general and family medicine workforce. Where do general and family physicians earn the most? Location appears to make a substantial difference. Among the highest average salaries reported by Data México in Q1 2026 were: Baja California Sur — MX$21,400 per month Guanajuato — MX$16,700 per month Chiapas — MX$16,500 per month The figure for Baja California Sur is almost twice the national average reported for the occupation. This illustrates why a national salary figure should be treated as a benchmark rather than an expectation for every physician. For a GP considering where to practise in Mexico, regional salary data may therefore be just as relevant as the national average. How large is Mexico's general and family physician workforce? The same dataset estimates that approximately 238,000 general and family physicians were employed in Mexico in Q1 2026. That compares with roughly 213,000 in Q4 2025. The change represents an increase of around 11.9% quarter on quarter in the estimated employed population. Mexico City remains one of the country's largest centres for general and family medicine employment, alongside other heavily populated states. The combination of changing workforce numbers and changing salaries is worth watching over subsequent quarters. A sustained rise in both would present a very different labour-market picture from a temporary quarterly movement. What do male and female general physicians earn? Data México also provides salary information by sex. For Q1 2026, it reports average monthly salaries of approximately: Women — MX$11,900 Men — MX$9,820 On the surface, that would mean female general and family physicians earned more than male physicians during the quarter. However, this finding needs particular caution. Data México warns that some of its salary estimates have low statistical precision, meaning demographic and regional comparisons should not be interpreted as definitive evidence of underlying pay differences without additional supporting data. What does the salary figure actually measure? This distinction is important for physicians comparing compensation internationally. The Data México figure is an occupational labour-market salary estimate. It should not automatically be interpreted as total physician compensation. Depending on how a physician practises, total economic income might also be affected by factors including: private consultations; multiple clinical positions; hospital appointments; additional shifts; self-employed medical activity; bonuses or allowances; academic work; and other professional income. Consequently, the MX$10,800 monthly figure is best viewed as an official labour-market benchmark for people classified as general and family physicians rather than a comprehensive measure of everything a Mexican GP may earn. How reliable is the data? The source itself places an important qualification on the salary statistics. Data México states that some salary estimates have low statistical precision and therefore should not be used to draw firm conclusions. That does not make the figures unusable. They remain valuable for understanding the direction, scale and geographical variation of earnings in the profession, particularly because they come from an official Mexican government data platform. But physicians should avoid treating individual quarterly or state-level estimates as guaranteed market rates. Longer-term trends and additional salary sources can provide a stronger picture. What should general and family physicians take from the latest figures? For GPs and family physicians, there are three particularly useful conclusions from the Q1 2026 data. First, the latest national benchmark is MX$10,800 per month, substantially higher than the figure recorded in the previous quarter. Second, where a physician works matters considerably. Some states report average salaries well above the national figure. Third, these statistics should be treated as labour-market indicators rather than exact measures of total physician compensation. For general and family physicians assessing career opportunities in Mexico, the most useful comparison may therefore not be simply “What does a GP earn in Mexico?” but rather: What are physicians in my specialty earning in the particular market where I want to practise? That is the comparison that becomes increasingly useful as more specialty- and location-specific compensation data become available. Source: Data México, Ministry of Economy, General and Family Physicians, Q1 2026. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Bluejay Diagnostics and Lovell Government Services have formed a distribution and co-marketing partnership to prepare Bluejay's Symphony diagnostic platform for access to US federal healthcare markets following regulatory authorisation. Lovell will support federal procurement opportunities across organisations including the Department of Veterans Affairs, Department of Defense, Military Health System and Indian Health Service. The partnership establishes commercial infrastructure in advance of potential US launch, while Bluejay's Symphony products remain subject to applicable FDA clearance or other required regulatory authorisation. Field Content Alert Type Deal Companies Bluejay Diagnostics; Lovell Government Services Deal Type Distribution, co-marketing and strategic partnership Asset or Company Symphony near-patient diagnostic platform Therapy Area(s) Diagnostics; acute care Technology or Modality Near-patient diagnostic platform Deal Value Financial terms were not disclosed Geography United States federal healthcare market What Happened Bluejay Diagnostics and Lovell Government Services entered into a distribution, co-marketing and strategic partnership to support future introduction of Bluejay products into US federal healthcare channels. Why It Matters The agreement gives Bluejay access to established federal contracting and procurement infrastructure across the VA, Department of Defense, Military Health System and other government healthcare organisations. Supporting Context Lovell will act as Bluejay's exclusive distributor for certain federal procurement opportunities requiring or favouring Service-Disabled Veteran-Owned Small Business status and will also participate in broader government-market opportunities. Strategic Rationale The partnership allows Bluejay to build federal commercial readiness in parallel with regulatory and manufacturing preparations rather than establishing government procurement infrastructure independently. Potential Impact If Bluejay's Symphony platform receives the required regulatory authorisation, the partnership could accelerate access to large US federal healthcare systems. Key Takeaway Bluejay has established a federal distribution pathway for its Symphony platform ahead of potential US regulatory clearance and commercial launch. What to Watch FDA regulatory progress for the Symphony platform and subsequent launch into VA, DoD and other federal healthcare channels. Primary Source Bluejay Diagnostics Relevant Date 8 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sernova and Seraxis have entered into a definitive merger agreement to create BetaNova Biotherapeutics, a new clinical-stage company focused on type 1 diabetes islet-cell replacement therapies. The merger combines Sernova's Cell Pouch bio-hybrid organ platform with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturing capabilities. Sernova and Seraxis shareholders are each expected to own approximately 50% of BetaNova, while a US$10 million financing is intended to support development of SR-02 and SR-03 and preparations for a potential Nasdaq listing. Field Content Alert Type Deal Companies Sernova Biotherapeutics; Seraxis Holdings Deal Type Definitive merger agreement Asset or Company BetaNova Biotherapeutics Therapy Area(s) Type 1 diabetes; regenerative medicine Technology or Modality Islet-cell replacement; stem cell-derived pancreatic islet cells; Cell Pouch bio-hybrid organ Deal Value US$10 million concurrent non-brokered convertible note financing; merger consideration structured so Sernova and Seraxis shareholders are each expected to own approximately 50% of BetaNova Geography United States; Canada What Happened Sernova and Seraxis entered into a definitive merger agreement to combine their businesses and technologies into a new company, BetaNova Biotherapeutics. Why It Matters The transaction brings together complementary islet-cell replacement technologies, development infrastructure and manufacturing capabilities in a single company focused on type 1 diabetes. Supporting Context BetaNova plans to advance SR-02 into a Phase 1/2 trial in type 1 diabetes, with first patient dosing expected in the first quarter of 2027, while SR-03 is being developed as a next-generation gene-edited immune-evasive islet-cell therapy. Strategic Rationale The merger combines Sernova's implantable Cell Pouch platform with Seraxis' stem cell-derived islet-cell technology and cGMP manufacturing to create an integrated regenerative-medicine company. Potential Impact If successful, the combined platform could advance cell-replacement approaches intended to restore insulin-producing function in people with type 1 diabetes. Key Takeaway Sernova and Seraxis are combining to form BetaNova Biotherapeutics, creating an integrated type 1 diabetes cell-therapy company backed by a US$10 million financing. What to Watch Shareholder approval and expected merger closing in November 2026, followed by planned SR-02 clinical dosing and potential Nasdaq listing preparations in 2027. Primary Source Sernova Biotherapeutics Relevant Date 8 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novacyt has commercially launched the IVDR-certified Yourgene Insight DPYD assay across regulated European markets to support identification of patients at increased risk of severe fluoropyrimidine toxicity. The molecular diagnostic detects 19 clinically relevant DPYD variants associated with dihydropyrimidine dehydrogenase deficiency and is intended to support safer use of fluoropyrimidine-based chemotherapy. The launch completes the assay's transition from its research-use-only version introduced in May 2026 to compliance with the European Union's In Vitro Diagnostic Regulation. Field Content Alert Type Approval Product Name Yourgene Insight DPYD assay Company Novacyt Regulatory Framework European Union In Vitro Diagnostic Regulation (IVDR) Approval Type IVDR certification and commercial launch Intended Use Detection of clinically relevant DPYD variants associated with increased risk of severe toxicity from fluoropyrimidine-based chemotherapy Variants Detected 19 clinically relevant DPYD variants Therapy Area(s) Oncology; pharmacogenomics; molecular diagnostics Geography European regulated markets What Happened Novacyt commercially launched the IVDR-certified Yourgene Insight DPYD assay following completion of its regulatory transition under the European Union's IVDR. Why It Matters DPYD genotyping can identify patients at increased risk of severe or potentially fatal toxicity from fluoropyrimidine chemotherapy, enabling treatment decisions to be adjusted before therapy begins. Supporting Context The assay was initially launched for research use only in May 2026 and expands the number of detectable DPYD variants to 19. Key Takeaway Novacyt has moved its expanded DPYD pharmacogenomic assay into regulated European clinical markets with IVDR certification. What to Watch Adoption of DPYD testing across European oncology pathways and expansion into additional regulated territories. Primary Source Novacyt Relevant Date 8 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Abbott's TactiFlex Duo Ablation Catheter, a dual-energy system combining pulsed-field ablation and radiofrequency energy for the treatment of atrial fibrillation. The catheter allows electrophysiologists to use pulsed-field ablation, radiofrequency energy or a combination of both during the same procedure, providing additional flexibility when treating challenging AFib cases. The approval was supported by Abbott's FlexPulse IDE study and expands the company's US pulsed-field ablation portfolio, with broader commercial adoption planned in the coming weeks. Field Content Alert Type Approval Device Name TactiFlex Duo Ablation Catheter, Sensor Enabled Company Abbott Regulatory Authority U.S. Food and Drug Administration Approval Type Medical device approval Indication Treatment of patients with challenging cases of atrial fibrillation Technology or Modality Dual-energy cardiac ablation catheter using pulsed-field ablation and radiofrequency energy Therapy Area(s) Cardiology; electrophysiology Geography United States What Happened The FDA approved Abbott's TactiFlex Duo Ablation Catheter for the treatment of atrial fibrillation. Why It Matters The device combines pulsed-field ablation and radiofrequency energy in a single catheter, allowing physicians to select or combine energy modalities during an AFib ablation procedure. Supporting Context The approval was supported by results from Abbott's FlexPulse IDE study, which evaluated safety and effectiveness in patients with paroxysmal atrial fibrillation. Key Takeaway FDA approval of TactiFlex Duo gives US electrophysiologists a new dual-energy ablation catheter for treating complex atrial fibrillation cases. What to Watch US commercial rollout and adoption of dual-energy ablation strategies across electrophysiology centres. Primary Source Abbott Relevant Date 8 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sudarshan Pharma has approved the acquisition of a 9.5% stake in US-based MedTherapy Biotechnology, expanding its exposure to oncology cell and gene therapy. The investment gives Sudarshan Pharma a strategic interest in MedTherapy Biotechnology, which is developing cancer therapies including CAR-T programmes and related cell and gene therapy technologies. The transaction supports Sudarshan Pharma's international expansion strategy while providing access to an emerging US biotechnology platform focused on advanced oncology treatments. Field Content Alert Type Deal Companies Sudarshan Pharma; MedTherapy Biotechnology Deal Type Strategic equity investment Asset or Company 9.5% stake in MedTherapy Biotechnology Therapy Area(s) Oncology Technology or Modality Cell and gene therapy; CAR-T Stake 9.5% Geography United States; India What Happened Sudarshan Pharma's board approved the acquisition of a 9.5% equity stake in US-based MedTherapy Biotechnology. Why It Matters The investment gives Sudarshan Pharma exposure to advanced oncology cell and gene therapy development and supports its expansion into the US biotechnology market. Supporting Context MedTherapy Biotechnology is focused on cancer therapeutics and has capabilities spanning CAR-T and other cell and gene therapy approaches. Strategic Rationale The investment broadens Sudarshan Pharma's oncology portfolio and provides a strategic foothold in an emerging US biotechnology company. Potential Impact The transaction could support future collaboration and commercial opportunities around advanced cancer therapies and international expansion. Key Takeaway Sudarshan Pharma is acquiring a 9.5% stake in MedTherapy Biotechnology as part of its expansion into oncology cell and gene therapy. What to Watch Completion of the investment and any subsequent development, manufacturing or commercial collaboration between the companies. Primary Source Business Standard Relevant Date 7 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer. The approval applies to patients whose ESR1 mutation is detected during first-line endocrine-based therapy and introduces a new treatment strategy designed to act before clinical disease progression. The decision was supported by results from the Phase III SERENA-6 trial, which evaluated switching endocrine therapy to camizestrant while continuing CDK4/6 inhibition following detection of an emerging ESR1 mutation. Field Content Alert Type Approval Drug Name Camizestrant Brand Name Etcamah Company AstraZeneca Regulatory Authority U.S. Food and Drug Administration Approval Type Accelerated approval Indication Adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation detected during first-line endocrine-based therapy Therapy Area(s) Oncology; breast cancer Combination Etcamah plus a CDK4/6 inhibitor Geography United States What Happened The FDA granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for eligible adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer. Why It Matters The approval introduces a treatment approach based on detecting emerging ESR1 resistance mutations during first-line therapy and switching endocrine treatment before clinical disease progression. Supporting Context The approval was supported by the Phase III SERENA-6 study evaluating camizestrant with continued CDK4/6 inhibition after detection of an ESR1 mutation. Key Takeaway Etcamah provides a new FDA-approved treatment option for patients with ESR1-mutated advanced HR-positive, HER2-negative breast cancer identified during first-line therapy. What to Watch Clinical uptake of ESR1 mutation monitoring and confirmatory evidence supporting the accelerated approval. Primary Source U.S. Food and Drug Administration Relevant Date 4 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Novartis India is looking at therapy-aligned acquisition opportunities while seeking to deepen its presence in India's Tier 2 and Tier 3 markets. The company's growth strategy combines potential acquisitions that complement its therapeutic focus with greater penetration beyond India's largest metropolitan markets. The plans signal a broader effort by Novartis India to strengthen its domestic footprint while maintaining alignment with priority therapy areas. Field Content Alert Type Corporate strategy update Company Novartis India Industry Area Pharmaceuticals Geography India Strategic Focus Therapy-aligned acquisitions and expansion into Tier 2 and Tier 3 markets What Happened Novartis India outlined plans to explore acquisition opportunities aligned with its therapeutic priorities while expanding its presence in Tier 2 and Tier 3 markets. Why It Matters The strategy could broaden Novartis India's domestic reach and provide additional growth opportunities while keeping potential acquisitions aligned with the company's existing therapeutic focus. Supporting Context The acquisition plans are prospective rather than a completed transaction, making the development a corporate strategy update rather than a Deals announcement. Key Takeaway Novartis India is pursuing a two-pronged growth strategy centred on therapy-aligned acquisition opportunities and deeper penetration of markets outside India's largest cities. What to Watch Potential acquisition targets and the execution of Novartis India's expansion strategy across Tier 2 and Tier 3 markets. Primary Source Business Standard Relevant Date 6 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com